4502.T - Takeda Pharmaceutical Company Limited
NEXT EARNINGS:
May 13, 2026
EPS Est: $10.42
|
Rev Est: $1.1T
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Market Cap:
9.19T
Volume:
2,467,100
Avg Volume:
4,907,550
52 Week Range:
3916-5840
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
0.08
Last Dividend:
$198.00
Exchange:
JPX
Country:
JP
Employees:
49,281
IPO Date:
2000-01-04
EPS (TTM):
68.36
P/E Ratio:
64.56
Revenue (TTM):
4.58T
Total Assets:
14.25T
Total Debt:
5.09T
Cash & Equiv:
233.74B
Rev Growth (5Y):
6.8%
EPS Growth (5Y):
19.2%
FCF Growth (5Y):
12.2%
ROCE:
3.1%
Debt/Equity:
0.73
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-01-29 | $64.93 | $42.61 | +52.4% | $1.2T | $1.2T | +1.2% |
| 2025-10-29 | $-8.16 | $21.61 | -137.8% | $1.1T | $1.2T | -8.2% |
| 2025-07-29 | $81.38 | $50.79 | +60.2% | $1.1T | $1.2T | -7.4% |
| 2025-05-07 | $-64.14 | $-8.59 | -646.6% | $1.1T | $1.0T | +1.0% |
| 2025-01-30 | $14.92 | $25.86 | -42.3% | $1.1T | $1.1T | +2.1% |
| 2024-10-31 | $58.14 | $32.80 | +77.3% | $1.2T | $1.2T | +2.0% |
| 2024-07-31 | $60.71 | $43.77 | +38.7% | $1.2T | $981.6B | +23.1% |
| 2024-05-09 | $-2.01 | $0.77 | -361.0% | $1.1T | $934.7B | +12.4% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.58T | 4.26T | 4.03T | 3.57T | 3.20T | 3.29T | 2.10T | 1.77T | 1.73T | 1.81T | 1.78T | 1.69T |
| Net Income | 107.93B | 144.07B | 317.02B | 230.06B | 376.00B | 44.24B | 135.19B | 186.89B | 114.94B | 80.17B | (145.78B) | 106.66B |
| EPS | 68.36 | 92.09 | 204.29 | 147.14 | 240.72 | 28.41 | 69.57 | 239.35 | 147.15 | 102.26 | -92.94 | 135.10 |
| Total Assets | 14.25T | 15.11T | 13.96T | 13.18T | 12.91T | 12.82T | 13.87T | 4.11T | 4.36T | 3.82T | 4.30T | 4.57T |
| Total Debt | 5.09T | 5.46T | 4.86T | 4.81T | 5.07T | 5.46T | 6.08T | 1.04T | 1.20T | 822.21B | 748.83B | 877.45B |
| Cash & Equivalents | 233.74B | 205.19B | 229.56B | 849.70B | 966.22B | 637.61B | 702.09B | 294.52B | 319.45B | 451.43B | 652.15B | 666.05B |
| Operating Cash Flow | 962.49B | 640.32B | 877.22B | 1.02T | 905.07B | 555.41B | 302.61B | 379.60B | 260.07B | 26.55B | 183.44B | 148.34B |
| Free Cash Flow | 761.70B | 464.90B | 736.56B | 897.97B | 793.87B | 428.33B | 224.93B | 312.60B | 198.41B | (22.21B) | 135.21B | 98.23B |
| FCF per Share | 482.43 | 297.17 | 474.65 | 574.33 | 508.24 | 275.06 | 233.94 | 400.35 | 254.01 | -28.33 | 171.94 | 124.42 |
| Book Value | 6.94T | 7.27T | 6.35T | 5.68T | 5.17T | 4.72T | 5.16T | 2.00T | 1.89T | 1.95T | 2.14T | 2.47T |
| Cash & ST Investments | 385.11B | 457.80B | 533.53B | 849.70B | 966.22B | 637.61B | 702.09B | 375.17B | 376.14B | 560.03B | 713.42B | 851.03B |
| ROC Equity | 0.02 | 0.02 | 0.05 | 0.04 | 0.07 | 0.01 | 0.03 | 0.09 | 0.06 | 0.04 | -0.07 | 0.04 |